Antares Pharma (ATRS) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Antares Pharma Reports Second Quarter 2015 Operating and Financial Results
August 10, 2015 7:00 AM EDTRecord Second Quarter Revenues Driven by Increased OTREXUP and Device Sales
EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the second quarter ended June 30, 2015. The Company reported revenue of $14.4 million and a net loss per share of $0.01 for the second quarter and revenue of $22.8 million and a net loss of $0.06 per share for the first half of 2015. Antares ended the second quarter with $58.1 million in cash, cash equivalents and investments and no debt.
Record second quarter results were... More
